EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial

Ronette L Kolotkin iD, Ole Kleist Jeppesen, James Baker-Knight, Sang Yeoup Lee, Asako Tokita, Takashi Kadowaki

Clinical Obesity · 2023-08 · 13 (4)

DOI: 10.1111/cob.12589 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Obesity, online erschienen am 11.03.2023. Verfasst von Ronette L Kolotkin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Quality of Life Consulting, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Quality of Life, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We assessed the effect of semaglutide 2.4 and 1.7 mg versus placebo on weight‐related quality of life (WRQOL) and health‐related quality of life (HRQOL) in the STEP 6 trial. Adults from East Asia (body mass index [BMI] ≥27.0 kg/m 2 with ≥2 weight‐related comorbidities, or ≥35.0 kg/m 2 with ≥1 weight‐related comorbidity) were randomized 4:1:2:1 to once‐weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks. WRQOL and HRQOL were assessed from baseline to Week 68 using the Impact of Weight on Quality of Life‐Lite Clinical Trials Version (IWQOL‐Lite‐CT) and the 36‐Item‐Short‐Form‐Survey‐version‐2.0 acute (SF‐36v2), with changes in scores by categories of baseline BMI (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeDiabetes Mellitus, Type 2AdultHumansEast Asian PeopleObesityPatient Reported Outcome MeasuresSemaglutide

Stichwörter der Autor:innen

East AsianIWQOL-Lite-CTSF-36v2obesitypatient-reported outcomessemaglutide

Substanzen

Semaglutide

Autor:innen und Institutionen

  • Quality of Life Consulting, Durham, North Carolina, USA.
  • Family Medicine and Community Health, Duke University School of Medicine, Durham, North Carolina, USA.
  • Centre of Health Research, Helse Førde Hospital Trust, Førde, Norway.
  • Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Family Medicine Clinic and Biomedical Research Institute, Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnam-do, South Korea.

ORCID-Profile: Ronette L Kolotkin

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Kolotkin, R. L., Jeppesen, O. K., Baker-Knight, J., Lee, S. Y., Tokita, A., & Kadowaki, T. (2023). Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial. Clinical Obesity, 13(4). https://doi.org/10.1111/cob.12589

Vancouver

Kolotkin RL, Jeppesen OK, Baker-Knight J, Lee SY, Tokita A, Kadowaki T. Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial. Clinical Obesity. 2023;13(4). doi:10.1111/cob.12589

BibTeX
@article{Kolotkin2023,
  author = {Kolotkin, Ronette L and Jeppesen, Ole Kleist and Baker-Knight, James and Lee, Sang Yeoup and Tokita, Asako and Kadowaki, Takashi},
  title = {Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial},
  journal = {Clinical Obesity},
  year = {2023},
  volume = {13},
  number = {4},
  doi = {10.1111/cob.12589}
}
Kostenlos starten →